Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-037712
Filing Date
2023-03-28
Accepted
2023-03-28 16:06:16
Documents
21

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm231836d4_def14a.htm   iXBRL DEF 14A 2126375
6 GRAPHIC lg_theravanbiopharma-4c.jpg GRAPHIC 104279
7 GRAPHIC sg_rickewinningham-bw.jpg GRAPHIC 11595
8 GRAPHIC bc_theravance-4c.jpg GRAPHIC 210404
9 GRAPHIC bc_netincome-4c.jpg GRAPHIC 189712
10 GRAPHIC bc_collaboration-4c.jpg GRAPHIC 163510
11 GRAPHIC px_01proxy-4c.jpg GRAPHIC 1121069
12 GRAPHIC px_02proxy-4c.jpg GRAPHIC 699130
  Complete submission text file 0001104659-23-037712.txt   9073165

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tbph-20221231.xsd EX-101.SCH 7998
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tbph-20221231_def.xml EX-101.DEF 6578
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20221231_lab.xml EX-101.LAB 13545
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20221231_pre.xml EX-101.PRE 5462
15 EXTRACTED XBRL INSTANCE DOCUMENT tm231836d4_def14a_htm.xml XML 237066
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36033 | Film No.: 23769535
SIC: 2834 Pharmaceutical Preparations